Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis

Abstract

Abstract: Objective To explore the mechanism of modulation of intestinal mucosal inflammatory factors by curcumin, the inhibitor of the transcriptional factor nuclear factor -κB (NF-κB), in rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis, and screen for a targeted therapeutic agent for treatment of inflammatory bowel disease (IBD). Methods Rats with TNBS-induced colitis were fed with diet containing 2.0% curcumin (treatment group), 0.5% sulfasalazine (SASP, positive control group), and normal diet (model group and negative control group). Changes in colonic mucosal histological scores were evaluated and the cytokine mRNA expressions in the colonic tissue assessed by semiquantitative reverse transcriptional PCR (RT-PCR). Results Treatment with curcumin ameliorated the histopathologic signs in rats with TNBS-induced intestinal inflammation. Curcumin and sulfasalazine obviously suppressed the high expression of proinfiammatory cytokine interleukin (IL)-1β mRNA and increased the low expression of IL-10 mRNA in the colonic mucosa. Expression of the anti-inflammatory cytokine IL-4 mRNA was detected in none of the groups. Conclusions Curcumin could modulate the expressions of IL-1β and IL-10 mRNA in murine model of IBD, which suggests the potential of curcumin as a targeted therapeutic agent for IBD.

CLC Number:

R285.5

JIAN Yan-ting¹, WANG Ji-de¹, MAI Guo-feng², ZHANG Ya-li¹, LAI Zhuo-sheng¹. Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis[J]. Journal of Southern Medical University, 2004, 24(12): 1353-1358.

References

[1] Kinoshita K, Sato K, Hori M, et al. Decrease in activity of smooth muscle L-type Ca²⁺ channels and its reversal by NF-kappaB inhibitors in Crohn’s colitis model [J]. Am J Physiol Gastrointest Liver Physiol, 2003, 285 (3):G483-93.
[2] Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor κappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis [J].Proc Natl Acad Sci USA, 2004, 101(15): 5634-9.
[3] LappasM, YeeK, PermezelM, et al. Sulphasalazine and BAY 11-7082 interfere with the NF-kappa B and IKK-beta pathway to regulate the release of pro-inflammatory cytokines from human adipose tissue and skeletal muscle, In Vitro [J]. Endocrinology,2004, [Epub chead of print].
[4] Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ appa B kinase activity[J]. J Immunol, 1999,163(6):3474-83.
[5] Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice [J]. J Exp Med,1995, 182(5): 1281-90.
[6] Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease[J]. Nature, 2001,411(6837):599-603.
[7] Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease [J]. Nature,2001, 411(6837): 603-6.
[8] Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB [J].J Biol Chem, 2001, 276(7): 4812-8.
[9] Monteleone G, Mann J, Monteleone I, et al. A failure oftransforming growth factor-betal negative regulation maintains sustained NF-κ appaB activation in gut inflammation[J]. J Biol Chem, 2004,279(6):3925-32.
[10] Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis [J]. World J Gastroenterol,2004, 10(10): 1521-5.
[11] Ferretti M, Casini Raggi, Vpizarro TT, et al. Neutralization of endogenous IL1 receptor antagonist exacerbates and prolongs inf lammation in rabbit immune colitis [J]. J Clin Invest, 1994, 94(1):449-53.
[12] Bickston S J, Cominelli F. Recombinant interleukin 10 for the treatment of active Crohn’s disease: lessons in biologic therapy [J].Gastroenterology, 2000, 119(6): 1781-3.
[13] Shibata Y, Taruishi M, Ashida T. Experimental ileitis in dogs and colitis in rats with trinitrobenzene sulfonic acid--colonoscopic and histopathologic studies [J]. Gastroenterol Jpn, 1993, 28(4): 518-27.
[14] Dijkstra G, Moshage H, Jansen PL. Blockade of NF-κ appaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease [J]? Scand J Gastroenterol Suppl, 2002,(236): 37-41.
[15] Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ appa B kinase activity[J]. J Immunol, 1999, 163(6): 3474-83.
[16] Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights [J].Annu Rev Immunol, 1996, 14: 649-83.